Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02043-2
Abstract: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status… read more here.
Keywords: egfr; tki; positive advanced; progression ... See more keywords